NCT05461820View on ClinicalTrials.gov

Effects of Different Treatment Schemes on the Regulation and Recurrence of Graves' Disease

PHASE4RecruitingINTERVENTIONAL
Enrollment

240

Participants

Timeline

Start Date

May 1, 2018

Primary Completion Date

December 31, 2023

Study Completion Date

July 31, 2030

Conditions
Graves DiseaseRelapseTreatmentDrug Withdrawal
Interventions
DRUG

Methimazole

Methimazole used in this study was produced by Merck, Germany, and its trade name is Thyrozol. The specification of this drug is 10mg/ tablet, and its validity period is 36 months. It was approved by FDA in 2009 and listed in China in 2011.

Trial Locations (1)

Unknown

RECRUITING

the First Affiliated Hospital of Nanjing Medical University, Nanjing

All Listed Sponsors
lead

The First Affiliated Hospital with Nanjing Medical University

OTHER